{"name":"Pablo Rodríguez del Rio","slug":"pablo-rodr-guez-del-rio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"\"Conventional\" regimen","genericName":"\"Conventional\" regimen","slug":"conventional-regimen","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"marketed"},{"name":"\"Rush\" regimen","genericName":"\"Rush\" regimen","slug":"rush-regimen","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"marketed"}]}],"pipeline":[{"name":"\"Conventional\" regimen","genericName":"\"Conventional\" regimen","slug":"conventional-regimen","phase":"marketed","mechanism":"This drug works by inhibiting the reuptake of norepinephrine, serotonin, and dopamine.","indications":["Attention deficit hyperactivity disorder (ADHD)","Major depressive disorder"],"catalyst":""},{"name":"\"Rush\" regimen","genericName":"\"Rush\" regimen","slug":"rush-regimen","phase":"marketed","mechanism":"Rush is a stimulant that increases alertness and energy by affecting the central nervous system.","indications":["Attention deficit hyperactivity disorder (ADHD)","Narcolepsy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}